Epstein Files Full PDF

CLICK HERE
Technopedia Center
PMB University Brochure
Faculty of Engineering and Computer Science
S1 Informatics S1 Information Systems S1 Information Technology S1 Computer Engineering S1 Electrical Engineering S1 Civil Engineering

faculty of Economics and Business
S1 Management S1 Accountancy

Faculty of Letters and Educational Sciences
S1 English literature S1 English language education S1 Mathematics education S1 Sports Education
teknopedia

  • Registerasi
  • Brosur UTI
  • Kip Scholarship Information
  • Performance
Flag Counter
  1. World Encyclopedia
  2. Epicillin - Wikipedia
Epicillin - Wikipedia
From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Epicillin
Clinical data
ATC code
  • J01CA07 (WHO)
Identifiers
IUPAC name
  • (2S,5R,6R)-6-[[(2R)-2-Amino-2-(1-cyclohexa-1,4-dienyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
CAS Number
  • 26774-90-3 checkY
PubChem CID
  • 71392
ChemSpider
  • 64486 ☒N
UNII
  • 3LU1L73C8Y
CompTox Dashboard (EPA)
  • DTXSID60181288 Edit this at Wikidata
ECHA InfoCard100.043.623 Edit this at Wikidata
Chemical and physical data
FormulaC16H21N3O4S
Molar mass351.42 g·mol−1
3D model (JSmol)
  • Interactive image
SMILES
  • O=C(O)[C@@H]2N3C(=O)[C@@H](NC(=O)[C@@H](C/1=C/C\C=C/C\1)N)[C@H]3SC2(C)C
InChI
  • InChI=1S/C16H21N3O4S/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8/h3-4,7,9-11,14H,5-6,17H2,1-2H3,(H,18,20)(H,22,23)/t9-,10-,11+,14-/m1/s1 ☒N
  • Key:RPBAFSBGYDKNRG-NJBDSQKTSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Epicillin (INN) is a penicillin antibiotic. It is not approved by the FDA for use in the United States.[citation needed]

It is an aminopenicillin.[1][2]

References

[edit]
  1. ^ Bergan T (1979). "Studies on aminopenicillin developments. Proceedings of a symposium. Concluding remarks". Infection. 7 (Suppl 5): S507-512. doi:10.1007/bf01659785. PMID 389828. S2CID 46974138.
  2. ^ Mombelli G (May 1981). "[Aminopenicillin: when, how, what kind?]". Schweizerische Medizinische Wochenschrift (in German). 111 (18): 641–5. PMID 7244588.
  • v
  • t
  • e
Antibacterials active on the cell wall and envelope (J01C-J01D)
β-lactams
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases
)
Penicillins (Penams)
Narrow
spectrum
β-lactamase sensitive
(1st generation)
  • Benzylpenicillin (G)#
  • Benzathine benzylpenicillin#
  • Procaine benzylpenicillin#
  • Phenoxymethylpenicillin (V)#
  • Propicillin‡
  • Pheneticillin‡
  • Azidocillin‡
  • Clometocillin‡
  • Penamecillin‡
β-lactamase resistant
(2nd generation)
  • Cloxacillin# (Dicloxacillin
  • Flucloxacillin)
  • Oxacillin
  • Nafcillin
  • Methicillin‡
Extended
spectrum
Aminopenicillins (3rd generation)
  • Amoxicillin#
  • Ampicillin# (Pivampicillin
  • Hetacillin‡
  • Bacampicillin‡
  • Lenampicillin
  • Metampicillin‡
  • Talampicillin‡)
  • Epicillin‡
Carboxypenicillins (4th generation)
  • Ticarcillin
  • Carbenicillin‡ / Carindacillin‡
  • Temocillin‡
Ureidopenicillins (4th generation)
  • Piperacillin
  • Azlocillin‡
  • Mezlocillin‡
Other
  • Mecillinam (Pivmecillinam)
  • Sulbenicillin‡
Carbapenems / Penems
  • Carbapenems (Ertapenem
  • Antipseudomonal (Doripenem
  • Imipenem
  • Meropenem)
  • Biapenem‡
  • Panipenem)
  • Penems (Faropenem
  • Ritipenem§
  • Sulopenem)
Cephems
Cephalosporins
Cephamycins
Carbacephems
1st generation
  • Cefazolin#
  • Cefalexin #
  • Cefadroxil
  • Cefapirin
  • Cefazedone‡
  • Cefazaflur‡
  • Cefradine‡
  • Cefroxadine‡
  • Ceftezole‡
  • Cefaloglycin‡
  • Cefacetrile‡
  • Cefalonium‡
  • Cefaloridine‡
  • Cefalotin
  • Cefatrizine‡
2nd generation
  • Cefaclor
  • Cefprozil
  • Cefuroxime
  • Cefuroxime axetil
  • Cefamandole‡
  • Cefonicid‡
  • Ceforanide‡
  • Cefuzonam‡
  • Cephamycin (Cefoxitin
  • Cefotetan
  • Cefminox‡
  • Cefbuperazone‡
  • Cefmetazole‡)
  • Carbacephem (Loracarbef‡)
3rd generation
  • Cefixime#
  • Ceftriaxone#
  • Cefotaxime#
  • Antipseudomonal (Ceftazidime#
  • Cefoperazone)
  • Cefdinir
  • Cefcapene
  • Cefdaloxime
  • Ceftizoxime
  • Cefmenoxime
  • Cefpiramide
  • Cefpodoxime
  • Ceftibuten
  • Cefditoren
  • Cefotiam‡
  • Cefetamet‡
  • Cefodizime‡
  • Cefpimizole‡
  • Cefsulodin‡
  • Cefteram‡
  • Ceftiolene‡
  • Oxacephem (Flomoxef
  • Latamoxef‡)
4th generation
  • Cefepime
  • Cefozopran‡
  • Cefpirome
  • Cefquinome‡
5th generation
  • Ceftaroline fosamil
  • Ceftolozane
  • Ceftobiprole
Siderophore
  • Cefiderocol#
Veterinary
  • Ceftiofur
  • Cefquinome
  • Cefovecin
Monobactams
  • Aztreonam
  • Tigemonam‡
  • Carumonam‡
  • Nocardicin A‡
β-lactamase inhibitors
  • Penam (Sulbactam
  • Tazobactam
  • Enmetazobactam)
  • Clavam (Clavulanic acid)
  • non-β-lactam (Avibactam
  • Durlobactam
  • Relebactam
  • Taniborbactam
  • Vaborbactam)
Combinations
  • Amoxicillin/clavulanic acid#
  • Ampicillin/flucloxacillin
  • Ampicillin/sulbactam (Sultamicillin)
  • Aztreonam/avibactam
  • Benzathine benzylpenicillin/procaine benzylpenicillin
  • Cefepime/enmetazobactam
  • Cefepime/sulbactam
  • Cefoperazone/sulbactam
  • Ceftazidime/avibactam
  • Ceftolozane/tazobactam
  • Imipenem/cilastatin#
  • Imipenem/cilastatin/relebactam
  • Meropenem/vaborbactam
  • Panipenem/betamipron
  • Piperacillin/tazobactam
  • Sulbactam/durlobactam
  • Sulopenem/probenecid
  • Ticarcillin/clavulanic acid
Polypeptides
Lipopeptides
  • Insert into bacterial cell wall causing perforation and depolarization: Daptomycin
  • Surfactin
Other
  • Inhibits PG elongation and crosslinking: Ramoplanin§
Intracellular
  • Inhibit PG subunit synthesis and transport: NAM synthesis inhibition
    • Fosfomycin
  • DADAL/AR inhibitors
    • Cycloserine
    • Terizidone
  • bactoprenol inhibitors
    • Bacitracin
Other
  • Hydrolyze NAM-NAG
    • Lysozyme
  • Tyrothricin
    • Gramicidin
    • Tyrocidine
  • Isoniazid#
  • Teixobactin
  • #WHO-EM
  • ‡Withdrawn from market
  • Clinical trials:
    • †Phase III
    • §Never to phase III
Stub icon

This systemic antibiotic-related article is a stub. You can help Wikipedia by adding missing information.

  • v
  • t
  • e
Retrieved from "https://teknopedia.ac.id/w/index.php?title=Epicillin&oldid=1330816133"
Categories:
  • Penicillins
  • Enantiopure drugs
  • Antibiotic stubs
Hidden categories:
  • CS1 German-language sources (de)
  • Articles with short description
  • Short description matches Wikidata
  • Short description is different from Wikidata
  • Articles with changed ChemSpider identifier
  • ECHA InfoCard ID from Wikidata
  • Articles with changed InChI identifier
  • Articles without EBI source
  • Chemical pages without DrugBank identifier
  • Articles without KEGG source
  • Drugs with no legal status
  • Drugboxes which contain changes to verified fields
  • Drugboxes which contain changes to watched fields
  • All articles with unsourced statements
  • Articles with unsourced statements from March 2023
  • All stub articles

  • indonesia
  • Polski
  • العربية
  • Deutsch
  • English
  • Español
  • Français
  • Italiano
  • مصرى
  • Nederlands
  • 日本語
  • Português
  • Sinugboanong Binisaya
  • Svenska
  • Українська
  • Tiếng Việt
  • Winaray
  • 中文
  • Русский
Sunting pranala
url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url url
Pusat Layanan

UNIVERSITAS TEKNOKRAT INDONESIA | ASEAN's Best Private University
Jl. ZA. Pagar Alam No.9 -11, Labuhan Ratu, Kec. Kedaton, Kota Bandar Lampung, Lampung 35132
Phone: (0721) 702022
Email: pmb@teknokrat.ac.id